| Literature DB >> 19681829 |
H-Y Sun1, J M Aguado, H Bonatti, G Forrest, K L Gupta, N Safdar, G T John, K J Pursell, P Muñoz, R Patel, J Fortun, P Martin-Davila, B Philippe, F Philit, A Tabah, N Terzi, V Chatelet, S Kusne, N Clark, E Blumberg, M B Julia, A Humar, S Houston, C Lass-Florl, L Johnson, E R Dubberke, M A Barron, O Lortholary, N Singh.
Abstract
Fifty-eight solid organ transplant recipients with zygomycosis were studied to assess the presentation, radiographic characteristics, risks for extra-pulmonary dissemination and mortality of pulmonary zygomycosis. Pulmonary zygomycosis was documented in 31 patients (53%) and developed a median of 5.5 months (interquartile range, 2-11 months) posttransplantation. In all, 74.2% (23/31) of the patients had zygomycosis limited to the lungs and 25.8% (8/31) had lung disease as part of disseminated zygomycosis; cutaneous/soft tissue (50%, 4/8) was the most common site of dissemination. Pulmonary disease presented most frequently as consolidation/mass lesions (29.0%), nodules (25.8%) and cavities (22.6%). Patients with disseminated disease were more likely to have Mycocladus corymbifer as the causative pathogen. The mortality rate at 90 days after the treatment was 45.2%. In summary, pulmonary zygomycosis is the most common manifestation in solid organ transplant recipients with zygomycosis, and disseminated disease often involves the cutaneous/soft tissue sites but not the brain.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19681829 DOI: 10.1111/j.1600-6143.2009.02754.x
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086